Francesco Cognetti

22.1k total citations · 1 hit paper
221 papers, 8.5k citations indexed

About

Francesco Cognetti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Francesco Cognetti has authored 221 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Oncology, 85 papers in Pulmonary and Respiratory Medicine and 48 papers in Molecular Biology. Recurrent topics in Francesco Cognetti's work include Cancer Treatment and Pharmacology (62 papers), HER2/EGFR in Cancer Research (37 papers) and Breast Cancer Treatment Studies (34 papers). Francesco Cognetti is often cited by papers focused on Cancer Treatment and Pharmacology (62 papers), HER2/EGFR in Cancer Research (37 papers) and Breast Cancer Treatment Studies (34 papers). Francesco Cognetti collaborates with scholars based in Italy, Malaysia and United States. Francesco Cognetti's co-authors include Michèle Milella, Alessandra Fabi, Diana Giannarelli, Emilio Bria, Paolo Carlini, Ludovica Ciuffreda, Isabella Sperduti, Federica Cuppone, G. Ferretti and Italia Falcone and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Francesco Cognetti

215 papers receiving 8.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

2005 1.2k citations Francesco Cognetti, Pierfranco Conté et al. profile →

Peers

Countries citing papers authored by Francesco Cognetti

Since Specialization

Citations

This map shows the geographic impact of Francesco Cognetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Cognetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Cognetti more than expected).

Fields of papers citing papers by Francesco Cognetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Cognetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Cognetti. The network helps show where Francesco Cognetti may publish in the future.

Co-authorship network of co-authors of Francesco Cognetti

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Cognetti. A scholar is included among the top collaborators of Francesco Cognetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Cognetti. Francesco Cognetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial 2021 ·Expert Review of Clinical Pharmacology ·Alessia Mennitto, Elena Verzoni, Francesco Cognetti, Rosalba Miceli, Michèle Milella, Alessandra Mosca, (unknown), Alessandra Bearz, Franco Morelli, Cinzia Ortega, Francesco Atzori, Maddalena Donini, Mélanie Claps, Valentina Guadalupi, Pierangela Sepe, Vera Cappelletti, Filippo de Braud, Giuseppe Procopio	7
2	Applicazione della medicina narrativa nella pratica clinica oncologica: l’impatto sull’operatore 2020 ·Recenti Progressi in Medicina ·(unknown), (unknown), (unknown), Alessandra Fabi, (unknown), (unknown), (unknown), Francesco Cognetti, Maria Cecilia Cercato	6
3	95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC) 2020 ·Annals of Oncology ·Matteo Lambertini, Valentina Guarneri, (unknown), Andrea Rocca, Filippo Montemurro, Michelino De Laurentiis, Monica Giordano, Sabino De Placido, Giancarlo Bisagni, Ornella Garrone, (unknown), Filippo Giovanardi, Francesco Cognetti, Laura Amaducci, Antônio Bernardo, Lorenzo Livi, Claudia Bighin, Francesca Poggio, Alberto Ballestrero, Lucia Del Mastro	1
4	Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial 2019 ·International Journal of Cancer ·Matteo Lambertini, Francesca Poggio, Marco Bruzzone, Benedetta Conte, Claudia Bighin, Evandro de Azambuja, Mario Giuliano, Michelino De Laurentiis, Francesco Cognetti, Alessandra Fabi, Giancarlo Bisagni, Antonio Durando, Anna Turletti, (unknown), Ornella Garrone, Fabio Puglisi, Filippo Montemurro, Marcello Ceppi, Lucia Del Mastro, (unknown)	11
5	L’immunoterapia nel tumore del polmone non a piccole cellule: ritorno al futuro 2019 ·Recenti Progressi in Medicina ·Michela Roberto, Andrea Botticelli, Fabiana Letizia Cecere, Francesco Cognetti, Raffaele Giusti, Alain Gelibter, Fabrizio Nelli, Marianna Nuti, Daniele Santini, Paolo Marchetti, (unknown)	1
6	Ado-Trastuzumab Emtansine (T-DM1) in HER2+ Advanced Breast Cancer Patients: does Pretreatment with Pertuzumab Matter? 2017 ·Future Oncology ·Alessandra Fabi, Diana Giannarelli, Luca Moscetti, Daniele Santini, Alberto Zambelli, Michelino De Laurentiis, Michele Caruso, Daniele Generali, Enrichetta Valle, V. Leonardi, Katia Cannita, Grazia Arpino, Gianfranco Filippelli, G. Ferretti, (unknown), Filippo Montemurro, Cecilia Nisticò, (unknown), Francesco Cognetti	20
7	Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate 2016 ·Anti-Cancer Drugs ·(unknown), Paolo Carlini, Michela Roberto, Maria Bassanelli, Lidia Strigari, (unknown), (unknown), Alessandra Felici, Maurizio Valeriani, Francesco Cognetti, Paolo Marchetti	5
8	Dose-finding study on a continuous dose of oral vinorelbine (VNR) in heavily pre-treated metastatic breast cancer (MBC) patients (pts) 2015 ·Annals of Oncology ·(unknown), Diana Giannarelli, G. Ferretti, Alessandra Fabi, Cecilia Nisticò, Francesco Cognetti, Paola Papaldo	0
9	Targeting bone metastatic cancer: Role of the mTOR pathway 2014 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Francesco Bertoldo, Franco Silvestris, Toni Ibrahim, Francesco Cognetti, Daniele Generali, Carla Ripamonti, Dino Amadori, Marco Colleoni, Pierfranco Conté, Lucia Del Mastro, Sabino De Placido, Cinzia Ortega, Daniele Santini	26
10	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments 2013 ·BMC Cancer ·Lucia Del Mastro, Alessandra Fabi, Mauro Mansutti, Michelino De Laurentiis, Antonio Durando, Domenico Franco Merlo, Paolo Bruzzi, Ignazia La Torre, (unknown), Gbenga Kazeem, Paolo Marchi, (unknown), Marco Venturini, Sabino De Placido, Francesco Cognetti	16
11	HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care 2011 ·Clinical Cancer Research ·Alessandra Fabi, Anna Di Benedetto, Giulio Metro, Letizia Perracchio, Cecilia Nisticò, Franco Di Filippo, Cristiana Ercolani, G. Ferretti, Elisa Melucci, Simonetta Buglioni, Isabella Sperduti, Paola Papaldo, Francesco Cognetti, Marcella Mottolese	72
12	Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine 2010 ·Annals of Oncology ·Giulio Metro, Jennifer Foglietta, Michelangelo Russillo, Lucia Stocchi, Antonello Vidiri, Diana Giannarelli, Lucio Crinò, Paola Papaldo, Marcella Mottolese, Francesco Cognetti, Alessandra Fabi, Stefania Gori	120
13	Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer 2009 ·The Breast Journal ·Giulio Metro, Diana Giannarelli, (unknown), Gaetano Lanzetta, (unknown), Paola Papaldo, Teresa Gamucci, Vito Lorusso, Marcella Mottolese, Emanuela Magnolfi, Francesco Cognetti, Alessandra Fabi	10
14	Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. 2008 ·PubMed ·Giulio Metro, Alessandra Fabi, Michelangelo Russillo, Paola Papaldo, Michelino De Laurentiis, G. Ferretti, (unknown), Carmen Nuzzo, (unknown), Patrizia Vici, (unknown), Alessandra Felici, Francesco Cognetti, Paolo Carlini	8
15	Unexpected clinical outcome in a patient with liver and brain metastasis from melanoma. 2008 ·PubMed ·Carmen Nuzzo, Massimo Zeuli, Virginia Ferraresi, Mariangela Ciccarese, (unknown), Francesco Cognetti	0
16	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies 2008 ·The Breast ·Alessandra Fabi, Giulio Metro, G. Ferretti, Diana Giannarelli, Serena Di Cosimo, Paola Papaldo, Marcella Mottolese, Paolo Carlini, Alessandra Felici, Michelangelo Russillo, Francesco Cognetti	42
17	HER2/neu role in breast cancer: from a prognostic foe to a predictive friend 2007 ·Current Opinion in Obstetrics & Gynecology ·G. Ferretti, Alessandra Felici, Paola Papaldo, Alessandra Fabi, Francesco Cognetti	83
18	Bio-pathologic Characteristics Related to Chromosome 11 Aneusomy and Cyclin D1 Gene Status in Surgically Resected Stage I and II Breast Cancer: Identification of an Adverse Prognostic Profile 2007 ·The American Journal of Surgical Pathology ·Marcella Mottolese, (unknown), Isabella Sperduti, Roberta Merola, Simonetta Buglioni, Anna Di Benedetto, (unknown), Letizia Perracchio, Irene Venturo, Francesco Cognetti, (unknown)	4
19	Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women? 2003 ·The Journal of Steroid Biochemistry and Molecular Biology ·Paolo Carlini, G. Ferretti, Serena Di Cosimo, (unknown), (unknown), Adriana Romiti, Federica Tomao, Antonio Frassoldati, Paola Papaldo, Alessandra Fabi, Enzo Maria Ruggeri, Francesco Cognetti	10
20	Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy 1993 ·Journal of Clinical Oncology ·A. Del Favero, Enzo Ballatori, (unknown), Maurizio Tonato, Fausto Roila, Verena De Angelis, C. Basurto, Sergio Bracarda, E. Corgna, M. Picciafuoco, L. Patoia, G. Favalli, Rita Garbelli, Umberto Bianchi, Giovanna Scarfone, Cristina Ferraris, Marco Bolis, Francesco Cognetti, (unknown)	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact